Mantle Cell Lymphoma | Specialty

Dr. Ritchie on Immunological Response to Venetoclax/Ibrutinib in R/R MCL

February 6th 2020

David Ritchie, MD, PhD, discusses the long-term immunological response to the combination of venetoclax and ibrutinib in relapsed/refractory mantle cell lymphoma.

Dr. Villa on the Efficacy of Induction Therapy With BR in MCL

February 5th 2020

Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, Department of Medicine, The University of British Columbia, discusses the efficacy of induction therapy with bendamustine plus rituximab (Rituxan) in mantle cell lymphoma (MCL).

Dr. Goy on the Utility of Novel Agents in MCL

February 4th 2020

Andre H. Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the utility of novel agents in mantle cell lymphoma (MCL).

Priority Review in RET Fusion+ NSCLC and Thyroid Cancers, Breakthrough Status in MDS, and More

January 30th 2020

MCL: FDA Approval of a Second-Generation BTK Inhibitor

January 30th 2020

CAR T-Cell Therapy and the Future Management of MCL

January 30th 2020

Mantle Cell Lymphoma: Chemotherapy-Free Treatment Options

January 30th 2020

BTK Inhibitors in MCL: AEs, Specificity, and Interactions

January 30th 2020

Selecting a BTK Inhibitor for Mantle Cell Lymphoma

January 30th 2020

Updates in Management of Mantle Cell Lymphoma

January 30th 2020

KTE-X19 MCL Application Enters EU Regulatory Pipeline

January 30th 2020

The European Medicines Agency has validated and is now evaluating a Marketing Authorization Application for the CAR T-cell therapy KTE-X19 for the treatment of adult patients with relapsed/refractory mantle cell lymphoma.

Dr. Ramakrishnan on Benefit of CAR T-Cell Therapy in MCL

January 22nd 2020

Praveen Ramakrishnan, MD, discusses the benefit of CAR T-cell therapy in patients with mantle cell lymphoma.

Dr. Wang on the ZUMA-2 Trial in Relapsed/Refractory MCL

January 21st 2020

Michael Wang, MD, discusses the results of the phase II ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Expert Highlights Advances in MCL and DLBCL

January 20th 2020

Charalambos (Babis) Andreadis, MD, MSCE, discusses immunotherapeutic advances in MCL and DLBCL based on data from the 2019 ASH Annual Meeting.

Dr. Wang on Precision Medicine in MCL

January 17th 2020

Michael Wang, MD, discusses the move towards precision medicine in mantle cell lymphoma.

Dr. Rule on the Next Steps for BTK Inhibitors in MCL

January 16th 2020

Simon Rule, MD, professor of hematology, University of Plymouth, discusses the next steps for ibrutinib (Imbruvica) and other BTK inhibitors in the treatment landscape of mantle cell lymphoma (MCL).

Dr. Villa on Induction Therapy With Bendamustine/Rituximab in MCL

January 15th 2020

Diego Villa, MD, MPH, discusses a retrospective analysis of bendamustine and rituximab as induction therapy in patients with transplant-eligible and -ineligible mantle cell lymphoma.

Dr. Goy on Preliminary Data With Ibrutinib/Venetoclax in Relapsed/Refractory MCL

January 14th 2020

Andre H. Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses preliminary data with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in relapsed/refractory mantle cell lymphoma (MCL).

Long-Term Follow-Up of Acalabrutinib in Patients With MCL and CLL

January 10th 2020

Kellie Ryan, MPH, discusses the importance of long-term follow-up with acalabrutinib in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).

Dr. Andreadis on CAR T-Cell Therapy in Relapsed/Refractory MCL

January 10th 2020

Charalambos (Babis) Andreadis, MD, MSCE, discusses the emergence of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.